drugset / Trial / NCT00449501

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

NCT00449501 ↗

Phase 3 Completed 134 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily.

Timeline

Start
2007-03
Primary completion
—
Completion
2007-11

Outcome

Missed primary endpoint

paper No significant differences were observed in patients' reports of perception, either daily versus weekly or predose versus postdose. PMID 19995138 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled

Indications